CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 48 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2019. The put-call ratio across all filers is 0.43 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $604,368 | -53.6% | 14,400 | -60.2% | 0.00% | -66.7% |
Q1 2023 | $1,302,476 | -56.1% | 36,200 | -45.6% | 0.00% | -62.5% |
Q4 2022 | $2,968,362 | -12.1% | 66,600 | -44.5% | 0.01% | -20.0% |
Q3 2022 | $3,376,000 | -45.5% | 120,100 | -47.8% | 0.01% | -44.4% |
Q2 2022 | $6,198,000 | +18.2% | 229,900 | +49.3% | 0.02% | +28.6% |
Q1 2022 | $5,245,000 | +125.1% | 154,000 | +155.4% | 0.01% | +133.3% |
Q4 2021 | $2,330,000 | -20.6% | 60,300 | -31.3% | 0.01% | -25.0% |
Q2 2021 | $2,934,000 | -32.3% | 87,736 | -58.3% | 0.01% | -33.3% |
Q1 2021 | $4,331,000 | -38.4% | 210,256 | -47.6% | 0.01% | -36.8% |
Q4 2020 | $7,035,000 | +7.0% | 401,556 | -9.4% | 0.02% | 0.0% |
Q3 2020 | $6,575,000 | +801.9% | 443,356 | +690.9% | 0.02% | +850.0% |
Q2 2020 | $729,000 | +1870.3% | 56,056 | +239.8% | 0.00% | – |
Q4 2019 | $37,000 | -14.0% | 16,497 | -19.1% | 0.00% | – |
Q3 2019 | $43,000 | -40.3% | 20,397 | -24.4% | 0.00% | – |
Q2 2019 | $72,000 | -51.0% | 26,997 | -9.7% | 0.00% | – |
Q1 2019 | $147,000 | – | 29,897 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,388,967 | $125,425,669 | 9.68% |
5AM Venture Management, LLC | 497,270 | $18,403,963 | 4.12% |
COMMODORE CAPITAL LP | 1,425,000 | $52,739,250 | 3.60% |
SILVERARC CAPITAL MANAGEMENT, LLC | 374,910 | $13,875,419 | 3.27% |
TSP Capital Management Group, LLC | 249,220 | $9,223,635 | 2.89% |
Eventide Asset Management | 3,327,132 | $123,137,155 | 2.11% |
Affinity Asset Advisors, LLC | 475,400 | $17,594,554 | 2.03% |
Novo Holdings A/S | 850,000 | $31,458,500 | 1.83% |
Bellevue Group AG | 2,971,615 | $109,979,471 | 1.79% |
Redmile Group, LLC | 718,723 | $26,599,938 | 1.61% |